C-Peptide was from First Patient only; linkThe C-Peptide news was all about the first patient. See link and excerpt. See also below about Echelon.
https://web.tmxmoney.com/article.php?newsid=4885529503800806&qm_symbol=SVA LONDON, ONTARIO - TheNewswire - October 16, 2019 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, is pleased to announce the detection of enduring levels of C-peptide (measured up to 30 days and ongoing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its ongoing Phase I/II Cell Pouch(TM) US clinical study of type-1 diabetes.
The detection of fasting C-peptide in the bloodstream of our first patient, in addition to Sernova's recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body's varied need for insulin production. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch.
"Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient's bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova's Cell Pouch," said Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. "We look forward to reporting ongoing results in additional patients as the trial progresses."
Echelon just might know something more than we retail crowd and have mixed information up. I am guessing that more than one pouch has now been installed. Sernova now has the coin to do so and Echelon's wording suggests same even if it has published the details incorrectly.
n.b. Echelon is allowed to get more information than we retail crowd.
jwall